Are Wall Street Analysts Predicting Humana Stock Will Climb or Sink?

Core Viewpoint - Humana Inc. has significantly underperformed the broader market and healthcare sector, with a notable decline in stock price over the past year and year-to-date [2][3]. Company Overview - Humana Inc. is headquartered in Louisville, Kentucky, and provides medical and specialty insurance products, with a market capitalization of $22.8 billion [1]. Stock Performance - Over the past year, Humana's stock has declined by 32.1%, while the S&P 500 Index has increased by 14.4% [2]. - Year-to-date, Humana's stock is down 29.2%, contrasting with a 1.4% rise in the S&P 500 [2]. - Compared to the iShares U.S. Healthcare Providers ETF, which has fallen about 14.4% over the past year, Humana's performance is notably worse [3]. Financial Results - In Q4, Humana reported an adjusted loss of $3.96 per share, which was better than Wall Street's expectation of $4.01 per share [6]. - The company's adjusted revenue for the quarter was $32.6 billion, exceeding forecasts of $31.9 billion [6]. - For the full fiscal year ending December 2025, analysts expect Humana's EPS to grow by 5.3% to $17.07 on a diluted basis [7]. Analyst Ratings - Among 27 analysts covering Humana, the consensus rating is a "Hold," with seven "Strong Buy," two "Moderate Buy," 15 "Holds," and three "Strong Sells" [7]. - The overall rating has become more bearish compared to the previous month, with Morgan Stanley downgrading Humana to "Underweight" with a price target of $174 [8]. - The mean price target of $279.91 suggests a 54.4% premium to current price levels, while the highest target of $344 indicates an upside potential of 89.7% [8].